Centers for Disease Control and Prevention (CDC) advisors set to balance updated Covid-19 boosters

Centers for Disease Control and Prevention (CDC) advisors set to balance updated Covid-19 boosters

Programming note: We will not be publishing the Prescription Pulse from Monday, August 29th to Monday, September 5th. We’ll get back to your inbox on Wednesday, September 7th.

CDC vaccine advisors meet next week To deliberate on the recommendation of Omicron’s COVID-19 booster shots.

FDA Commissioner Robert Califf The health care system wants to generate more clinical evidence.

A new report from House Democrats on the Coronavirus Crisis Select Subcommittee Reveals how much pressure the Trump administration has put on the Food and Drug Administration over Covid product permits.

It’s Friday. you welcome in Prescription pulse. We thought it was supposed to be a quiet August holiday. We apologize for the inconvenience.

Send tips and feedback to David Lim ([email protected] or Tweet embed), Lauren Gardner ([email protected] or Tweet embedor Catherine Elaine Foley[email protected] or Tweet embed).

CDC Panel for Meeting on Omicron EnhancersThe Centers for Disease Control and Prevention (CDC) independent vaccine advisors will meet Thursday and Friday next week to discuss the recommendation to use updated Covid-19 boosters to cover the BA.4 and BA.5 omicron strains that have dominated US infections this summer. The meeting comes after Pfizer, and as of Wednesday, Moderna has applied to the Food and Drug Administration (FDA) for an emergency use authorization for its Omicron products.

This sets the timeline for the FDA’s decision sometime next week. But the agency will not hold a meeting of its independent advisory committee on vaccines, arguing that the committee’s June 28 discussion covered enough ground for regulators to make their own calls.

“The FDA does not have any new questions that warrant the committee’s input,” Commissioner Robert Califf said Tweet Thursday in wide topic About the agency’s position as it reviews the applications of the two companies. “When new enhancers become available, they are expected to help provide greater protection against currently prevalent strains,” he added.

External concern: Some medical experts have Regulators urged to postpone green lighting shots Until manufacturers have human clinical data about its effectiveness. Pfizer and Moderna’s applications are based in part on early data on the effects of their enhancers in mice since an FDA order to focus on BA.4 and BA.5 strains rather than the first Omicron variant didn’t come until the end of June.

Paul Offit, an infectious disease expert at Children’s Hospital of Philadelphia on the FDA’s expert panel, told Lauren he was “unpleasantly surprised” that the committee wouldn’t meet to publicly evaluate data for what he considers a new product.

“If you consider this vaccine as some kind of magic bullet, people will be disappointed” when they become mildly ill, Offit said.

Management take: Ashish Jha, the White House’s Covid-19 response coordinator, has optimistically touted the prospect of reformulated reinforcers, saying that “all the data points to [they] It should be very effective against new variants.”

“The bottom line of the big picture is that these are major improvements in our vaccines in terms of their ability to prevent infection, prevent transmission, and certainly prevent serious illness and death,” Jha said of bivalent boosters during the US Chamber of Commerce. It happened on August 16th.

Offit questioned the administration’s position — urging a massive vaccination campaign in the fall to reduce the amount of virus circulating rather than designing recommendations for those most at risk of severe disease — given the record of mRNA vaccines in neutralizing antibodies that declines after three to six months. “I think it’s like a leaky sieve,” Offit said.

HHS HOLDING COMMERCIALIZATION . TRANSITION PLANNING MEETINGThe federal health department is meeting with pharmacies, service providers, government agencies, consumer groups and industry on August 30 for a virtual meeting to plan for the potential transition of Covid-19 vaccines and treatments to the commercial market. The meeting will be attended by leadership from the CDC, CMS, FDA, NIH, the Department of Health Resources and Services, and the Department of Strategic Preparedness and Response.

There will be two separate sessions: one will focus on marketing plans for Covid-19 vaccines, while the second will focus on treatments. Discussion topics include reimbursement and coverage, regulatory issues, and how products are made available to uninsured and uninsured people, according to an event invitation obtained by POLITICO.

“As this process will take months and close coordination with stakeholders across the ongoing healthcare chain, HHS is working closely with these stakeholders to plan and ensure that the transition occurs smoothly when the time is right,” a HHS spokesperson said.

Calif: We need to generate more evidenceAcademics, health systems and professional societies should prioritize generating more clinical evidence to help the Food and Drug Administration more quickly understand the risks and benefits profile of medicinal products, according to FDA Commissioner Robert Califf.

“When FDA decisions generate controversy, it is often when the system fails to provide reliable evidence demonstrating the risks and benefits of an intervention within a relevant time frame,” Cliff wrote in JAMA earlier this week. “The gap between FDA clearance or approval of a medicinal product (particularly when the accelerated approval pathway is used) and use of the product to treat patients must be bridged by an active clinical research system that generates evidence that patients, clinicians, and health systems need to make informed decisions.”

Conference report shows Trump White House pressure from the Food and Drug Administration on Covid treatmentsDemocrats on the House Select Subcommittee on the Coronavirus Crisis released a report on Wednesday, detailing how top Trump officials lobbied the Food and Drug Administration over coronavirus permits, Catherine said.

The report’s findings aren’t all that surprising, but they offer new color through emails, texts, and official testimonies from former Food and Drug Administration Commissioner Stephen Hahn about how some of those efforts continued inside the White House throughout the summer and fall of 2020.

On hydroxychloroquine: After the US Food and Drug Administration (FDA) revoked the authorization of hydroxychloroquine after data emerged showing it was ineffective and harmful to Covid patients, Trump trade advisor Peter Navarro and coronavirus response volunteer Stephen Hatfill pushed the Food and Drug Administration to reauthorize the drug. Hatfill described the row between White House officials and the Food and Drug Administration as an imminent “knife fight.”

On Fauci: According to the report, Hatfill pushed to fire Anthony Fauci throughout the fall after the director of the National Institute of Allergy and Infectious Diseases refused to push the White House toward hydroxychloroquine. In September 2020, Hatfill told Navarro, “You really need to think about what might happen over the next couple of months if this little idiot and his Covid treatment plate aren’t fired.”

On vaccinations: Hahn testified before the subcommittee that the White House was not happy with the FDA’s requirement that late-stage Covid-19 vaccine trials include a 60-day safety follow-up — which would delay its authorization until after the 2020 election.

And on Navarro’s emails: This report provides further evidence that Navarro used his personal email for presidential matters. The Justice Department sued Navarro to get him to turn over other emails, first revealed by a separate report from the subcommittee, sent from his personal email account.

Washington awaits Biden’s nomination With the midterm elections looming, close watchers of the regulator are waiting for Biden to nominate someone to lead the small but powerful Office of Information and Regulatory Affairs, Politico’s Adam Kancrin reports.

The office, tasked with reviewing regulations, could play a big role in Biden’s last two years as the government implements key elements of the climate, health and tax law just passed by Democrats.

“OIRA is always at the center of administrative activity — the joke is that it is the most powerful agency that no one has ever heard of,” said Sharon Block, who served as its acting president during Biden’s first year. “Now, it becomes more important.”

Food and Drug Administration On Tuesday published the final guidance For tobacco manufacturers to design and conduct studies depicting tobacco products and intent.

Food and Drug Administration On Thursday, it published its annual report On the state of pharmaceutical quality.

OIG HHS post a note Summing up his findings, in the first quarter of 2022, eight drug codes met CMS’ price substitution criteria and had their average sales price above the manufacturer’s average price by 5 percent or more.

CMS On Thursday she finished her final plan To delay the payment model for radiation oncology indefinitely.

#Centers #Disease #Control #Prevention #CDC #advisors #set #balance #updated #Covid19 #boosters

Leave a Comment

Your email address will not be published.